Literature DB >> 22050605

Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective.

Mari B Elstrand1, Berit Sandstad, Halldis Oksefjell, Ben Davidson, Claes G Tropé.   

Abstract

OBJECTIVE: We aimed to evaluate prognostic factors impacting on overall survival during a 20 year period with substantial changes in surgical approach and chemotherapy management of patients with epithelial ovarian carcinoma stage IV.
DESIGN: A retrospective population-based study.
SETTING: The Norwegian Radium Hospital during 1985-2005. POPULATION: Three hundred and ninety-four patients with epithelial ovarian carcinoma stage IV treated at the Norwegian Radium Hospital.
METHODS: The cohort was divided into two groups (1985-1995 and 1996-2005), and clinical and pathological characteristics were compared. Univariate and multivariate analyses were performed to identify prognostic factors during 1985-1995, 1996-2005 and 1985-2005. MAIN OUTCOME MEASURES: Prognostic factors and overall survival in the three periods.
RESULTS: Median overall survival improved from 1985-1995 to 1996-2005 (from 1.3 to 2.1 years). More patients had macroscopic radical surgery (28 vs. 11%), received neoadjuvant chemotherapy and were treated with platinum-taxane combination therapy from 1996-2005 compared to 1985-1995. Patients with primary surgery had improved median overall survival from 1996-2005 compared to 1985-1995. In multivariate analyses, surgical approach was not a prognostic factor for overall survival, but chemotherapy was during 1985-2005. Postoperative residual tumor was a prognostic factor for overall survival in all periods.
CONCLUSIONS: Macroscopic radical surgery is a strong prognostic factor for overall survival and is achievable in a subset of patients with epithelial ovarian carcinoma stage IV. Improved selection criteria for what treatment algorithm to choose for patients with epithelial ovarian carcinoma stage IV are warranted.
© 2012 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2012 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Mesh:

Year:  2012        PMID: 22050605     DOI: 10.1111/j.1600-0412.2011.01316.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

Review 1.  Prognostic biomarkers in endometrial and ovarian carcinoma.

Authors:  Xavier Matias-Guiu; Ben Davidson
Journal:  Virchows Arch       Date:  2014-02-07       Impact factor: 4.064

2.  Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma.

Authors:  E T Taube; C Denkert; K Pietzner; M Dietel; J Sehouli; S Darb-Esfahani
Journal:  Virchows Arch       Date:  2014-12-19       Impact factor: 4.064

3.  Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.

Authors:  M Mizuno; H Kajiyama; K Shibata; K Mizuno; M Kawai; T Nagasaka; F Kikkawa
Journal:  Br J Cancer       Date:  2015-03-24       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.